Research programme: peptide drug conjugates - Decoy Therapeutics
Latest Information Update: 30 Jul 2025
At a glance
- Originator Decoy Therapeutics
- Class Antineoplastics; Peptide drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer
Most Recent Events
- 09 Jul 2025 Early research in Colorectal cancer in USA (unspecified route) prior to July 2025 (Decoy Therapeutics pipeline, July 2025)